Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines –NEW YORK, March 18, ...

Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin ("MICVO," formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 ...